Eichenfield LF, Flohr C, Sidbury R, et al. - Findings demonstrate effectiveness as well as good tolerability of oral abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis (AD).

• In this phase 3, randomized, double-blind, placebo-controlled study (JADE TEEN), a total of 285 adolescents with moderate-to-severe AD were randomized to once-daily oral abrocitinib, 200 mg or 100 mg, or placebo for 12 weeks in combination with topical therapy.

• Substantially more patients who received abrocitinib (200 mg or 100 mg) vs placebo achieved an Investigator’s Global Assessment response or clear or almost clear, at least 75% improvement in Eczema Area and Severity Index response, and/or at least 4-point improvement in Peak Pruritus Numerical Rating Scale response.

• Serious adverse events occurred in fewer than 3% of patients.